Literature DB >> 17134048

Pharmacokinetic alterations in obesity.

Jane B Lee1, P Shane Winstead, Aaron M Cook.   

Abstract

Although some medications have established dosing adjustments for obesity (Table 2), it remains unknown for the majority of medications if dosing adjustment is warranted. It is important to remember dosage adjustments may not be as simple as doubling an antibiotic dose because a patient is morbidly obese. Individualizing drug dosing is imperative in the obese, postoperative patient to ensure they simultaneously have therapeutic serum concentrations without drug toxicity. Much of what has been learned from studies in obese patients is that the pharmacokinetic alterations of medications are variable. Broad application of dosing guidelines even among medications within the same therapeutic class is likely not appropriate. An increased emphasis in researching the effects of obesity on the fate of medications is of paramount importance as the obese population grows. Practitioners should use caution and be vigilant in monitoring pharmacotherapy in obese individuals.

Entities:  

Mesh:

Year:  2006        PMID: 17134048     DOI: 10.3928/01477447-20061101-08

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  8 in total

1.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation.

Authors:  Molly H Thompson; Sylvia H Wilson; Brittany L Toussaint; Cameron L Jordan; Genevieve L Hayes; Brian P McKinzie; Bethany J Wolf; Larry C Field
Journal:  J Clin Anesth       Date:  2016-05-19       Impact factor: 9.452

3.  Risk factors for acute kidney injury following orthotopic liver transplantation: the impact of changes in renal function while patients await transplantation.

Authors:  Jose I Iglesias; John A DePalma; Jerrold S Levine
Journal:  BMC Nephrol       Date:  2010-11-08       Impact factor: 2.388

Review 4.  Vancomycin Dosing in Children With Overweight or Obesity: A Systematic Review and Meta-analysis.

Authors:  Manaswitha Khare; Aniqa Azim; Garrett Kneese; Meredith Haag; Kelsey Weinstein; Kyung E Rhee; Byron Alexander Foster
Journal:  Hosp Pediatr       Date:  2020-03-25

5.  Evaluation of extended interval dosing aminoglycosides in the morbidly obese population.

Authors:  Ashley L Ross; Jennifer L Tharp; Gerald R Hobbs; Richard McKnight; Aaron Cumpston
Journal:  Adv Pharmacol Sci       Date:  2013-08-19

6.  Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.

Authors:  Benjamin H Freed; Akhil Narang; Nicole M Bhave; Peter Czobor; Victor Mor-Avi; Emily R Zaran; Kristen M Turner; Kevin P Cavanaugh; Sonal Chandra; Sara M Tanaka; Michael H Davidson; Roberto M Lang; Amit R Patel
Journal:  J Cardiovasc Magn Reson       Date:  2013-12-21       Impact factor: 5.364

7.  Mercury Exposure in Mother-Children Pairs in A Seafood Eating Population: Body Burden and Related Factors.

Authors:  Shamshad Karatela; Neil Ward; Janis Paterson
Journal:  Int J Environ Res Public Health       Date:  2019-06-25       Impact factor: 3.390

8.  Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery.

Authors:  Kate Mostoller; Rebecca Wrishko; Lata Maganti; W Joseph Herring; Mariëlle van Zutphen-van Geffen
Journal:  Clin Transl Sci       Date:  2020-12-16       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.